Boston Trust Walden Corp Boosts Stake in Teleflex Incorporated (NYSE:TFX)

Boston Trust Walden Corp raised its holdings in Teleflex Incorporated (NYSE:TFX) by 21.2% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 283,562 shares of the medical technology company’s stock after acquiring an additional 49,649 shares during the period. Boston Trust Walden Corp’s holdings in Teleflex were worth $70,131,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Teleflex in the 1st quarter worth $2,467,000. ProShare Advisors LLC raised its holdings in shares of Teleflex by 34.1% during the 1st quarter. ProShare Advisors LLC now owns 12,200 shares of the medical technology company’s stock valued at $2,759,000 after buying an additional 3,105 shares in the last quarter. Tidal Investments LLC lifted its position in Teleflex by 214.7% in the 1st quarter. Tidal Investments LLC now owns 6,644 shares of the medical technology company’s stock worth $1,503,000 after buying an additional 4,533 shares during the last quarter. Russell Investments Group Ltd. grew its position in Teleflex by 15.8% during the first quarter. Russell Investments Group Ltd. now owns 18,838 shares of the medical technology company’s stock valued at $4,245,000 after acquiring an additional 2,570 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new position in shares of Teleflex during the first quarter worth approximately $537,000. Institutional investors own 95.62% of the company’s stock.

Teleflex Trading Down 0.8 %

NYSE TFX traded down $1.99 on Friday, hitting $233.63. The company’s stock had a trading volume of 252,156 shares, compared to its average volume of 362,949. The firm has a market cap of $11.01 billion, a P/E ratio of 41.95, a PEG ratio of 2.15 and a beta of 1.16. Teleflex Incorporated has a 52-week low of $177.63 and a 52-week high of $257.85. The company’s 50-day simple moving average is $241.03 and its 200 day simple moving average is $223.68. The company has a current ratio of 2.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.36.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, August 1st. The medical technology company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.33 by $0.09. The company had revenue of $749.70 million during the quarter, compared to analyst estimates of $762.98 million. Teleflex had a return on equity of 14.51% and a net margin of 8.76%. The firm’s revenue was up .9% on a year-over-year basis. During the same quarter last year, the firm posted $3.41 earnings per share. Research analysts predict that Teleflex Incorporated will post 13.97 EPS for the current fiscal year.

Teleflex Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, September 16th. Investors of record on Thursday, August 15th were given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 0.58%. The ex-dividend date was Thursday, August 15th. Teleflex’s dividend payout ratio is currently 24.42%.

Analysts Set New Price Targets

Several equities analysts recently commented on TFX shares. Stephens increased their target price on shares of Teleflex from $275.00 to $290.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Piper Sandler upgraded Teleflex from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $205.00 to $245.00 in a report on Monday, July 1st. Royal Bank of Canada increased their target price on Teleflex from $260.00 to $275.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Finally, Truist Financial lifted their price target on Teleflex from $247.00 to $255.00 and gave the stock a “hold” rating in a research note on Monday, October 14th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $268.86.

Insider Buying and Selling

In other Teleflex news, Director Stuart A. Randle sold 2,674 shares of Teleflex stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $238.93, for a total transaction of $638,898.82. Following the sale, the director now directly owns 5,496 shares of the company’s stock, valued at approximately $1,313,159.28. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.43% of the stock is owned by insiders.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.